Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Cancer J. 2011 Nov;17(6):465–476. doi: 10.1097/PPO.0b013e31823dec8d

Table 6.

Studies with 2nd-generation TKI as Frontline Therapy in CML

Study Drug N % Response at 12 months
CCyR MMR
Phase II-MDACC86 Nilotinib 400 mg twice daily 67 97 81
Phase II-MDACC12 Dasatinib 100 mg once daily 62 98 71
Phase II-
GIMEMA88 		Nilotinib 400 mg twice daily 73 96 85
Phase III-
ENESTnd91 		Nilotinib 300 mg twice daily 282 80 55
Nilotinib 400 mg twice daily 281 78 51
Imatinib 400 mg once daily 283 65 27
Phase III-
DASISION93 		Dasatinib 100 mg once daily 259 83 46
Imatinib 400 mg once daily 260 72 28
Phase III-BELA95 Bosutinib 500 mg once daily 250 70 39
Imatinib 400 mg once daily 252 68 26

Abbreviations: CCyR, Complete Cytogenetic Response; ENESTnd, Evaluation of Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed patients; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; MDACC, M.D. Anderson Cancer Center; MMR, Major Molecular Response.